Clinical Trials Arena June 6, 2024
Abigail Beaney

Novo Nordisk senior vice president Thomas Senderovitz said that big pharma needs to have more involvement in AI regulation.

Pharmaceutical companies need more involvement with agencies as they develop AI regulations.

At the Veeva R&D Summit at the Marriott Madrid Auditorium, Novo Nordisk senior vice president Thomas Senderovitz said that pharma companies need to have more involvement as agencies develop these regulations.

Senderovitz is working with partners from other pharmaceutical companies, including James Weatherall, vice president of data science and AI in the R&D department at AstraZeneca, to try and work with the agencies as they construct guidance.

“The challenge is that you have different regulatory systems that do not always have the same view,” Senderovitz explained.

“In Europe, you...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Biotechnology, Conferences / Podcast, Govt Agencies, Pharma, Pharma / Biotech, Regulations, Technology, Trends
Bringing genomics closer to patients: 3 takeaways from Henry Ford Health
Merck enters $2B licensing deal for weight loss drug
What are pharmacy benefit managers? A health economist explains how lack of competition drives up drug prices
How Medicare Negotiated Drug Prices Compare to Other Countries
The Fed's Warnings On Inflation Are Bad News For Biotech Startups

Share This Article